KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Assets: 2017-2024

Historic Non-Current Assets for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $1.9 billion.

  • Amneal Pharmaceuticals' Non-Current Assets fell 9.56% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 9.56%. This contributed to the annual value of $1.9 billion for FY2024, which is 8.64% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Non-Current Assets stood at $1.9 billion for FY2024, which was down 8.64% from $2.1 billion recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Non-Current Assets peaked at $2.5 billion during FY2020, and registered a low of $1.9 billion during FY2024.
  • Moreover, its 3-year median value for Non-Current Assets was $2.1 billion (2023), whereas its average is $2.1 billion.
  • Data for Amneal Pharmaceuticals' Non-Current Assets shows a maximum YoY decreased of 12.26% (in 2023) over the last 5 years.
  • Over the past 5 years, Amneal Pharmaceuticals' Non-Current Assets (Yearly) stood at $2.5 billion in 2020, then declined by 1.42% to $2.4 billion in 2021, then dropped by 1.32% to $2.4 billion in 2022, then declined by 12.26% to $2.1 billion in 2023, then declined by 8.64% to $1.9 billion in 2024.